Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization

Timothy W. Olsen, Nancy M. Benegas, Andrea C. Joplin, Tony Evangelista, Elizabeth A. Mindrup, Edward J. Holland

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Objective: To investigate the immunosuppresive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty. Design: Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. Results: By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addition, corneal neovascularization was markedly reduced in the treated animals. Conclusion: The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.

Original languageEnglish (US)
Pages (from-to)1471-1475
Number of pages5
JournalArchives of ophthalmology
Issue number11
StatePublished - Nov 1994

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization'. Together they form a unique fingerprint.

Cite this